Impedimed Limited

Impedimed Limited

0.00
USD
+0.00
(+69.23%)
-0.01EPS
18.27MMarket Cap
Feb 25Next Earn

Total Valuation

USD

As of June 30, 2026, Impedimed Ltd carries a market capitalization of 18.27M, placing it among publicly traded companies globally. Its enterprise value stands at 19.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap18.27M
Enterprise Value19.17M

Important Dates

Impedimed Ltd's next confirmed earnings release is scheduled for February 25, 2027.

Earnings Date2/25/2027

Share Statistics

As of June 30, 2026, Impedimed Ltd has 3.66B shares outstanding.

Shares Outstanding3.66B

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 1.05, and the price-to-book ratio stands at 2.59.

PS Ratio1.05
PB Ratio2.59
P/TBV Ratio1,466.36

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 1.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 19.17M versus a market cap of 18.27M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.90

Financial Position

As of June 30, 2026, Impedimed Ltd maintains a current ratio of 3.81, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 162.91, indicating elevated leverage, while an interest coverage ratio of -4.19 demonstrates limited ability to service its debt obligations.

Current Ratio3.81
Quick Ratio3.10
Debt / Equity162.91
Debt / EBITDA-0.91
Interest Coverage-4.19

Financial Efficiency

USD

Over the twelve months ended June 30, 2026, Impedimed Ltd posted a negative return on equity (ROE) of -162.35, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -65.27, reflecting losses generated across the asset base. The company generates approximately 153,224.28 in revenue per employee across its workforce of 66.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.20 indicates how many times Impedimed Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-162.35
Return on Assets (ROA)-65.27
Revenue Per Employee153,224.28
Employee Count66.00
Inventory Turnover1.20

Taxes

USD

Over the twelve months ended June 30, 2026, Impedimed Ltd recorded 17,993.08 in income tax expense. The company reported a pretax loss of -17.22M and -17.24M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax17,993.08

Stock Price Statistics

USD

As of the close on November 9, 2026, Impedimed Ltd's stock has declined approximately 62.71% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.06.

52-Week Price Change-62.71%
50-Day Moving Average0.01
200-Day Moving Average0.06

Income Statement

USD

Over the twelve months ended June 30, 2026, Impedimed Ltd generated 10.11M in revenue and converted that into -17.24M in net income, yielding earnings per share of -0.01. EBITDA reached -12.62M, while operating income came in at -15.54M.

Revenue10.11M
Gross Profit8.84M
Operating Income-15.54M
Pretax Income-17.22M
Net Income-17.24M
EBITDA-12.62M
EBIT-15.54M
Earnings Per Share (EPS)-0.01

Balance Sheet

USD

As of June 30, 2026, Impedimed Ltd holds 10.58M in cash and equivalents against 11.49M in total debt, resulting in a net debt position of 554,325.26. Total book value stands at 7.05M, with working capital of 12.01M providing operational flexibility.

Cash & Cash Equivalents10.58M
Total Debt11.49M
Net Debt554,325.26
Equity (Book Value)7.05M
Working Capital12.01M

Cash Flow

USD

These figures cover the twelve months ended June 30, 2026.

Capital Expenditures-879,584.78

Margins

Over the twelve months ended June 30, 2026, Impedimed Ltd posted a gross margin of 87.39, reflecting its pricing power and cost economics. The operating margin of -153.69 and net profit margin of -170.44 provide insight into operational efficiency.

Gross Margin87.39
Operating Margin-153.69
Pretax Margin-170.27
Profit Margin-170.44
EBITDA Margin-124.81

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -49.29, meaning Impedimed Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-49.29

Stock Splits

Impedimed Ltd's most recent stock split took place on April 3, 2020 with a 250:259 split ratio.

Last Split Date4/3/2020
Split Ratio250:259

Scores

As of June 30, 2026, Impedimed Ltd has an Altman Z-Score of -22.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-22.60